TY - JOUR
T1 - Mayo Clinic and North Central Cancer Treatment Group hot flash studies
T2 - A 20-year experience
AU - Loprinzi, Charles L.
AU - Barton, Debra L.
AU - Sloan, Jeff A.
AU - Novotny, Paul J.
AU - Dakhil, Shaker R.
AU - Verdirame, Joseph D.
AU - Knutson, Wilma H.
AU - Kelaghan, Joseph
AU - Christensen, Brad
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2008/7
Y1 - 2008/7
N2 - Objective: This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group. Design: Prospective clinical trials performed by these investigators are illustrated, described, and discussed. Results: Ten randomized, controlled (eight placebo controlled), double-blind clinical trials were conducted involving a total of 1,581 women and three placebo-controlled, double-blind clinical trials involving a total of 329 men were conducted. In addition, 14 pilot trials, having involved more than 325 participants to date, were conducted. Conclusions: Data from the pilot trials have given direction for substances that ought to be further explored in more definitive studies. In men, randomized studies demonstrate that hot flashes are markedly decreased by low doses of megestrol acetate, moderately decreased by gabapentin, but not substantially decreased by clonidine. Results from the randomized trials in women demonstrate that hot flashes are markedly decreased by relatively low doses of progestational agents (megestrol acetate and medroxyprogesterone acetate), moderately decreased by venlafaxine, mildly to moderately decreased by fluoxetine, mildly decreased by clonidine, but not substantially decreased by vitamin E, a soy phytoestrogen product, or black cohosh. Last, the data investigated in these studies support the hypothesis that, for the treatment of hot flashes in women, the results of therapeutic maneuvers are similar regardless of whether the patient has a history of breast cancer and/or is taking tamoxifen.
AB - Objective: This project was designed to provide an overview of hot flash studies conducted over the past two decades at the Mayo Clinic and in the North Central Cancer Treatment Group. Design: Prospective clinical trials performed by these investigators are illustrated, described, and discussed. Results: Ten randomized, controlled (eight placebo controlled), double-blind clinical trials were conducted involving a total of 1,581 women and three placebo-controlled, double-blind clinical trials involving a total of 329 men were conducted. In addition, 14 pilot trials, having involved more than 325 participants to date, were conducted. Conclusions: Data from the pilot trials have given direction for substances that ought to be further explored in more definitive studies. In men, randomized studies demonstrate that hot flashes are markedly decreased by low doses of megestrol acetate, moderately decreased by gabapentin, but not substantially decreased by clonidine. Results from the randomized trials in women demonstrate that hot flashes are markedly decreased by relatively low doses of progestational agents (megestrol acetate and medroxyprogesterone acetate), moderately decreased by venlafaxine, mildly to moderately decreased by fluoxetine, mildly decreased by clonidine, but not substantially decreased by vitamin E, a soy phytoestrogen product, or black cohosh. Last, the data investigated in these studies support the hypothesis that, for the treatment of hot flashes in women, the results of therapeutic maneuvers are similar regardless of whether the patient has a history of breast cancer and/or is taking tamoxifen.
KW - Breast cancer
KW - Hot flashes
KW - Hot flushes
UR - http://www.scopus.com/inward/record.url?scp=51449099396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51449099396&partnerID=8YFLogxK
U2 - 10.1097/gme.0b013e3181679150
DO - 10.1097/gme.0b013e3181679150
M3 - Review article
C2 - 18427355
AN - SCOPUS:51449099396
SN - 1072-3714
VL - 15
SP - 655
EP - 660
JO - Menopause
JF - Menopause
IS - 4
ER -